Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HPGDS | O60760 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16763424 | 0.93 | ALPL (0.55) | ALPLMAPTRAB9ANPC1KMT2A | |
| SCHEMBL7008825 | 0.91 | ALPL (0.50) | ALPLMAPTRAB9ANPC1KMT2A | |
| SCHEMBL1430763 | 0.87 | ALPL (0.55) | ALPLMAPTRAB9ANPC1KMT2A | |
| SCHEMBL1456258 | 0.85 | MAPK1 (0.57) | ALPLMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1456739 | 0.85 | ALPL (0.54) | ALPLMAPTRAB9ANPC1KMT2A | |
| SCHEMBL6712776 | 0.85 | ALPL (0.48) | ALPLMAPTRAB9ANPC1KMT2A | |
| SCHEMBL23500795 | 0.84 | ALPL (0.56) | ALPLMAPTRAB9ANPC1KMT2A | |
| SCHEMBL13742999 | 0.84 | ALPL (0.47) | ALPLMAPTRAB9ANPC1KMT2A | |
| SCHEMBL23929236 | 0.83 | HPGDS (0.57) | ALPLMAPTRAB9ANPC1KMT2A | |
| SCHEMBL1817376 | 0.83 | RAB9A (0.53) | ALPLMAPTRAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114369064-B | Preparation method of sildenafil intermediate | 北京莱瑞森医药科技有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-114369064-A | Preparation method of sildenafil intermediate | 北京莱瑞森医药科技有限公司 | 2022-04-19 | — | — | CN | claimed |
| EP-3099689-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2022-01-26 | — | — | EP | claimed |
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-07-10 | — | — | US | claimed |
| US-20170066771-A1 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-03-09 | — | — | US | claimed |
| EP-3099689-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2016-12-07 | — | — | EP | claimed |
| WO-2015114647-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-08-06 | — | — | WO | claimed |
| US-6960661-B2 | [7-(3-chloro-4-methoxybenzlamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid, synthesis thereof and intermediates used therein | MERCK PATENT GMBH (DE) | 2005-11-01 | — | — | US | claimed |
| US-20040053945-A1 | Process for the preparation of a pyrazolo[4,3-d]pyrimidine derivative | MERCK PATENT GMBH (DE) | 2004-03-18 | — | — | US | claimed |
| CN-114369064-B | Preparation method of sildenafil intermediate | 北京莱瑞森医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-114369064-B | Preparation method of sildenafil intermediate | 北京莱瑞森医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-110272389-B | Method for synthesizing 4-polyfluoroalkyl-3, 5-dicarbonyl pyrazole compound | 福州大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-114369064-A | Preparation method of sildenafil intermediate | 北京莱瑞森医药科技有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114369064-A | Preparation method of sildenafil intermediate | 北京莱瑞森医药科技有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5346901-A | Treatment of angina, hypertension, heart failure and atherosclerosis | PFIZER INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5272147-A | Pyrazolopyrimidinone antianginal agents | PFIZER INC. (US) | 1993-12-21 | — | — | US | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0526004-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1993-02-03 | — | — | EP | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | PDE5A, PDE3A, PDE3B | ALPL 269/4885MAPT 3388/4885RAB9A 1632/4885 |
| US-20170066771-A1 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | PDE5A, PDE3A, PDE3B | ALPL 269/4885MAPT 3388/4885RAB9A 1632/4885 |
| US-20040053945-A1 | Process for the preparation of a pyrazolo[4,3-d]pyrimidine derivative | HPD, DDC, KMO | ALPL 4027/4885MAPT 2814/4885RAB9A 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.